NCT05694715View on ClinicalTrials.gov

Combination Therapy in Cancers With Mutations in DNA Repair Genes

PHASE1RecruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions

Metastatic Solid TumorBRCA1 MutationBRCA2 MutationATM Gene MutationPALB2 Gene Mutation

Interventions

DRUG

Niraparib

Given orally

DRUG

Irinotecan

Given intravenously (IV)

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

University of California, San Francisco

OTHER